ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of “Buy” by Brokerages

Shares of ProQR Therapeutics (NASDAQ:PRQR) have received a consensus recommendation of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $8.83.

A number of brokerages have recently issued reports on PRQR. StockNews.com lowered shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research report on Friday, January 10th. They issued an “outperform” rating and a $15.00 price objective on the stock. JMP Securities restated a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR opened at $2.15 on Friday. The stock has a market capitalization of $175.61 million, a PE ratio of -6.72 and a beta of 0.30. The company has a fifty day moving average of $2.83 and a two-hundred day moving average of $2.56. ProQR Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. The firm had revenue of $4.22 million for the quarter, compared to analyst estimates of $4.75 million. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. Research analysts forecast that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Institutional Trading of ProQR Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Ballentine Partners LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter valued at $61,000. OneDigital Investment Advisors LLC lifted its holdings in ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 15,550 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares in the last quarter. Finally, Privium Fund Management B.V. boosted its position in shares of ProQR Therapeutics by 0.9% during the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after purchasing an additional 51,663 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).